Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn whether neratinib is safe and effective in treating
women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.